COMMUNIQUÉS West-GlobeNewswire

Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
21/02/2018
TUSTIN, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a company working to improve patient lives by providing high quality biologics manufacturing services to [...]
Allscripts to present at 2018 RBC Capital Markets Global Healthcare Conference
21/02/2018
CHICAGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ) today announced that certain members of its management team will present at the 2018 RBC Capital Markets Global Healthcare Conference, to be held at [...]
Premier Biomedical Inc., CEO William Hartman Returns to Uptick Newswire’s “Stock Day” with Everett Jolly
21/02/2018
PHOENIX, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical Inc., (OTC:BIEI) President & CEO, William A. Hartman today reviewed operational accomplishments of 2017 and expectations for 2018 in an interview on [...]
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
21/02/2018
--Ended 2017 with a healthy cash position of $380M -- --Recently announced FDA approval and launch of Glatopa ® 40 mg-- CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ) [...]
Dr. Eugene Sun Appointed to Novan Board of Directors
21/02/2018
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEO Will provide expert perspective on the clinical application of the underlying nitric oxide science Will chair [...]
Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
21/02/2018
CRANBURY, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results [...]
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology
21/02/2018
Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K delta and unique complementary inhibition of casein kinase-1 (CK1) epsilon Single agent umbralisib was well tolerated [...]
Recro Pharma to Host Analyst and Investor Day on February 28, 2018
21/02/2018
MALVERN, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH ), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today [...]
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors
21/02/2018
HOUSTON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
21/02/2018
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth [...]
FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018
21/02/2018
SAN FRANCISCO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN ), a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017 financial results on [...]
Update: Natus to Present at Raymond James 39th Annual Institutional Investors Conference
21/02/2018
PLEASANTON, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) today announced that Jonathan Kennedy, Executive Vice-President and Chief Financial Officer will present at the Raymond [...]
Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
21/02/2018
BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC ) (NASDAQ: CYCCP ) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target [...]
Purepoint Uranium Acquires Strategic Land Positions in the Athabasca Basin, Saskatchewan
21/02/2018
TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “ Company ” or “ Purepoint ”) (TSX.V:PTU) today reported that since October, 2017 it has acquired through staking an additional 52,479 [...]
Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
21/02/2018
LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders [...]
CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting
21/02/2018
OXNARD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced Gene Salkind, M.D. joined the company’s Advisory Board and also [...]
New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
21/02/2018
Copenhagen, 2018-02-21 10:00 CET (GLOBE NEWSWIRE) -- Allergy immunotherapy company ALK today announced that its sublingual allergy immunotherapy (SLIT) tablet ACARIZAX ® is now available on prescription in France for [...]
Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
21/02/2018
Press release - No. 5/2018 Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia Last patient visit concluded in the multinational Phase 3 trial, with [...]
Veritas Pharma Provides Corporate Update on Q1 2018
21/02/2018
VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) , (“Veritas” or the “Company”) is pleased to provide an official corporate update on its [...]

Pages